Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 108

1.

Additive manufacturing of polymer-derived ceramics.

Eckel ZC, Zhou C, Martin JH, Jacobsen AJ, Carter WB, Schaedler TA.

Science. 2016 Jan 1;351(6268):58-62. doi: 10.1126/science.aad2688.

2.

Materials science. Toward lighter, stiffer materials.

Schaedler TA, Jacobsen AJ, Carter WB.

Science. 2013 Sep 13;341(6151):1181-2. doi: 10.1126/science.1243996. No abstract available.

PMID:
24031005
3.

HER2-positive male breast cancer with thyroid cancer: an institutional report and review of literature.

Bardhan P, Bui MM, Minton S, Loftus L, Carter WB, Laronga C, Ismail-Khan R.

Ann Clin Lab Sci. 2012 Spring;42(2):135-9. Review.

PMID:
22585608
4.

Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer.

Munster PN, Moore AP, Ismail-Khan R, Cox CE, Lacevic M, Gross-King M, Xu P, Carter WB, Minton SE.

J Clin Oncol. 2012 Feb 10;30(5):533-8. doi: 10.1200/JCO.2011.34.6890. Epub 2012 Jan 9.

5.

Role of axillary staging in women diagnosed with ductal carcinoma in situ with microinvasion.

Pimiento JM, Lee MC, Esposito NN, Kiluk JV, Khakpour N, Carter WB, Han G, Laronga C.

J Oncol Pract. 2011 Sep;7(5):309-13. doi: 10.1200/JOP.2010.000096. Epub 2011 Jul 27.

6.

Ultralight metallic microlattices.

Schaedler TA, Jacobsen AJ, Torrents A, Sorensen AE, Lian J, Greer JR, Valdevit L, Carter WB.

Science. 2011 Nov 18;334(6058):962-5. doi: 10.1126/science.1211649.

7.

Institutional variation in the surgical treatment of breast cancer: a study of the NCCN.

Greenberg CC, Lipsitz SR, Hughes ME, Edge SB, Theriault R, Wilson JL, Carter WB, Blayney DW, Niland J, Weeks JC.

Ann Surg. 2011 Aug;254(2):339-45. doi: 10.1097/SLA.0b013e3182263bb0.

8.

Management of isolated Adrenal Lesions in Cancer Patients.

McLean K, Lilienfeld H, Caracciolo JT, Hoffe S, Tourtelot JB, Carter WB.

Cancer Control. 2011 Apr;18(2):113-26. Review.

PMID:
21451454
9.

New treatments and shifting paradigms in differentiated thyroid cancer management.

Carter WB, Tourtelot JB, Savell JG, Lilienfeld H.

Cancer Control. 2011 Apr;18(2):96-103. Review.

PMID:
21451452
10.

Changing paradigms in the treatment of endocrine tumors.

Lilienfeld H, Carter WB.

Cancer Control. 2011 Apr;18(2):80-1. No abstract available.

PMID:
21451449
11.

Invasive breast cancer.

Carlson RW, Allred DC, Anderson BO, Burstein HJ, Carter WB, Edge SB, Erban JK, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Ljung BM, Mankoff DA, Marcom PK, Mayer IA, McCormick B, Pierce LJ, Reed EC, Sachdev J, Smith ML, Somlo G, Ward JH, Wolff AC, Zellars R; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2011 Feb;9(2):136-222. No abstract available.

PMID:
21310842
12.

A mammaglobin-A targeting agent for noninvasive detection of breast cancer metastasis in lymph nodes.

Tafreshi NK, Enkemann SA, Bui MM, Lloyd MC, Abrahams D, Huynh AS, Kim J, Grobmyer SR, Carter WB, Vagner J, Gillies RJ, Morse DL.

Cancer Res. 2011 Feb 1;71(3):1050-9. doi: 10.1158/0008-5472.CAN-10-3091. Epub 2010 Dec 17.

13.

Breast cancer: noninvasive and special situations.

Carlson RW, Allred DC, Anderson BO, Burstein HJ, Carter WB, Edge SB, Erban JK, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Ljung BM, Marcom PK, Mayer IA, McCormick B, Pierce LJ, Reed EC, Smith ML, Somlo G, Topham NS, Ward JH, Winer EP, Wolff AC.

J Natl Compr Canc Netw. 2010 Oct;8(10):1182-207. No abstract available.

PMID:
20971842
14.

Consequences of axillary ultrasound in patients with T2 or greater invasive breast cancers.

Lee MC, Eatrides J, Chau A, Han G, Kiluk JV, Khakpour N, Cox CE, Carter WB, Laronga C.

Ann Surg Oncol. 2011 Jan;18(1):72-7. doi: 10.1245/s10434-010-1171-4. Epub 2010 Jun 29.

PMID:
20585876
15.

Adenoid cystic carcinoma of the breast: a review of a single institution's experience.

Sarnaik AA, Meade T, King J, Acs G, Hoover S, Cox CE, Carter WB, Laronga C.

Breast J. 2010 Mar-Apr;16(2):208-10. doi: 10.1111/j.1524-4741.2009.00876.x. Epub 2009 Dec 16. Review. No abstract available.

PMID:
20030648
16.

Indications for sentinel lymph node biopsy in the setting of prophylactic mastectomy.

Laronga C, Lee MC, McGuire KP, Meade T, Carter WB, Hoover S, Cox CE.

J Am Coll Surg. 2009 Dec;209(6):746-52; quiz 800-1. doi: 10.1016/j.jamcollsurg.2009.08.010. Epub 2009 Oct 17.

PMID:
19959044
17.

Breast cancer. Clinical practice guidelines in oncology.

Carlson RW, Allred DC, Anderson BO, Burstein HJ, Carter WB, Edge SB, Erban JK, Farrar WB, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Jahanzeb M, Kiel K, Ljung BM, Marcom PK, Mayer IA, McCormick B, Nabell LM, Pierce LJ, Reed EC, Smith ML, Somlo G, Theriault RL, Topham NS, Ward JH, Winer EP, Wolff AC; NCCN Breast Cancer Clinical Practice Guidelines Panel.

J Natl Compr Canc Netw. 2009 Feb;7(2):122-92. Review. No abstract available.

PMID:
19200416
18.

Tumor-induced upregulation of Twist, Snail, and Slug represses the activity of the human VE-cadherin promoter.

Lopez D, Niu G, Huber P, Carter WB.

Arch Biochem Biophys. 2009 Feb;482(1-2):77-82. doi: 10.1016/j.abb.2008.11.016. Epub 2008 Nov 24.

PMID:
19046938
19.

Chemotherapy use for hormone receptor-positive, lymph node-negative breast cancer.

Hassett MJ, Hughes ME, Niland JC, Edge SB, Theriault RL, Wong YN, Wilson J, Carter WB, Blayney DW, Weeks JC.

J Clin Oncol. 2008 Dec 1;26(34):5553-60. doi: 10.1200/JCO.2008.17.9705. Epub 2008 Oct 27.

20.

Purified human chorionic gonadotropin induces apoptosis in breast cancer.

Lopez D, Sekharam M, Coppola D, Carter WB.

Mol Cancer Ther. 2008 Sep;7(9):2837-44. doi: 10.1158/1535-7163.MCT-08-0339.

21.

Mechanisms of HER2-induced endothelial cell retraction.

Carter WB, Niu G, Ward MD, Small G, Hahn JE, Muffly BJ.

Ann Surg Oncol. 2007 Oct;14(10):2971-8. Epub 2007 Jun 26.

PMID:
17593333
22.

Invasive breast cancer.

Carlson RW, Anderson BO, Burstein HJ, Carter WB, Edge SB, Farrar WB, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Jahanzeb M, Ljung BM, Kiel K, Marks LB, McCormick B, Nabell LM, Pierce LJ, Reed EC, Silver SM, Smith ML, Somlo G, Theriault RL, Ward JH, Winer EP, Wolff AC.

J Natl Compr Canc Netw. 2007 Mar;5(3):246-312. Review. No abstract available.

PMID:
17439758
24.

Makers of angiogenesis in breast cancer.

Kiluk J, Carter WB.

MLO Med Lab Obs. 2006 Aug;38(8):10, 12, 16; quiz 18-9. No abstract available.

PMID:
16983871
25.

Paget's disease in the era of sentinel lymph node biopsy.

Laronga C, Hasson D, Hoover S, Cox J, Cantor A, Cox C, Carter WB.

Am J Surg. 2006 Oct;192(4):481-3.

PMID:
16978954
26.

Diagnostic accuracy of mammography, clinical examination, US, and MR imaging in preoperative assessment of breast cancer.

Berg WA, Gutierrez L, NessAiver MS, Carter WB, Bhargavan M, Lewis RS, Ioffe OB.

Radiology. 2004 Dec;233(3):830-49. Epub 2004 Oct 14.

PMID:
15486214
27.

Tunable surface oxidation states in Si/SiO2 nanostructures prepared from Si/SiQ2 mixtures and phenol hydroxylation activity.

Gole JL, Shinall BD, Iretskii AV, White MG, Carter WB, Erickson AS.

Chemphyschem. 2003 Sep 15;4(9):1016-21. No abstract available.

PMID:
14562451
28.

Health-related quality of life, depressive symptoms, anemia, and malnutrition at hemodialysis initiation.

Walters BA, Hays RD, Spritzer KL, Fridman M, Carter WB.

Am J Kidney Dis. 2002 Dec;40(6):1185-94.

PMID:
12460037
29.

Impact of age and colony-stimulating factor use on hospital length of stay for febrile neutropenia in CHOP-treated non-Hodgkin's lymphoma.

Chrischilles E, Delgado DJ, Stolshek BS, Lawless G, Fridman M, Carter WB.

Cancer Control. 2002 May-Jun;9(3):203-11.

PMID:
12060818
30.

Delivering adjuvant chemotherapy to women with early-stage breast carcinoma: current patterns of care.

Link BK, Budd GT, Scott S, Dickman E, Paul D, Lawless G, Lee MW, Fridman M, Ford J, Carter WB; Oncology Practice Pattern Study Working Group.

Cancer. 2001 Sep 15;92(6):1354-67.

PMID:
11745211
31.

Parathyroid-produced angiopoietin-2 modulates angiogenic response.

Carter WB, Ward MD.

Surgery. 2001 Dec;130(6):1019-27.

PMID:
11742332
32.

The impact of age on delivered dose intensity and hospitalizations for febrile neutropenia in patients with intermediate-grade non-Hodgkin's lymphoma receiving initial CHOP chemotherapy: a risk factor analysis.

Morrison VA, Picozzi V, Scott S, Pohlman B, Dickman E, Lee M, Lawless G, Kerr R, Caggiano V, Delgado D, Fridman M, Ford J, Carter WB; Oncology Practice Pattern Study Working Group.

Clin Lymphoma. 2001 Jun;2(1):47-56.

PMID:
11707870
33.

Patterns of chemotherapy administration in patients with intermediate-grade non-Hodgkin's lymphoma.

Picozzi VJ, Pohlman BL, Morrison VA, Lawless GD, Lee MW, Kerr RO, Ford JM, Delgado DJ, Fridman M, Carter WB.

Oncology (Williston Park). 2001 Oct;15(10):1296-306; discussion 1310-1, 1314.

34.

HER2 signaling--induced microvessel dismantling.

Carter WB.

Surgery. 2001 Aug;130(2):382-7.

PMID:
11490375
35.

HER2/neu over-expression induces endothelial cell retraction.

Carter WB, Hoying JB, Boswell C, Williams SK.

Int J Cancer. 2001 Feb 1;91(3):295-9.

36.

Multiple ectopic parathyroid glands.

Maxwell R, Carter WB, Smith RM, Perry RR.

Am Surg. 2000 Nov;66(11):1028-31.

PMID:
11090012
37.

Development of subscales from the symptoms/problems and effects of kidney disease scales of the kidney disease quality of life instrument.

Rao S, Carter WB, Mapes DL, Kallich JD, Kamberg CJ, Spritzer KL, Hays RD.

Clin Ther. 2000 Sep;22(9):1099-111.

PMID:
11048907
38.

Parathyroid-induced angiogenesis is VEGF-dependent.

Carter WB, Uy K, Ward MD, Hoying JB.

Surgery. 2000 Sep;128(3):458-64.

PMID:
10965318
39.

HER2 regulatory control of angiopoietin-2 in breast cancer.

Carter WB, Ward MD.

Surgery. 2000 Aug;128(2):153-8.

PMID:
10922985
40.
41.

Stimulation of angiogenesis by canine parathyroid tissue.

Carter WB, Crowell SL, Boswell CA, Williams SK.

Surgery. 1996 Dec;120(6):1089-94.

PMID:
8957500
42.

Using the theory of reasoned action (TRA) to understand the decision to use condoms in an STD clinic population.

Baker SA, Morrison DM, Carter WB, Verdon MS.

Health Educ Q. 1996 Nov;23(4):528-42.

PMID:
8910029
43.

A review of health-related quality-of-life measures used in end-stage renal disease.

Edgell ET, Coons SJ, Carter WB, Kallich JD, Mapes D, Damush TM, Hays RD.

Clin Ther. 1996 Sep-Oct;18(5):887-938. Review.

PMID:
8930432
44.

Characteristics of health promotion programs in Federal worksites: findings from the Federal Employee Worksite Project.

Carter WB, Omenn GS, Martin M, Crump C, Grunbaum JA, Williams OD.

Am J Health Promot. 1995 Nov-Dec;10(2):140-7.

PMID:
10160048
45.

Comparing the performance of health status measures for healthy older adults.

Andresen EM, Patrick DL, Carter WB, Malmgren JA.

J Am Geriatr Soc. 1995 Sep;43(9):1030-4.

PMID:
7657920
46.

The RAND Kidney Disease and Quality of Life instrument.

Kallich JD, Hays RD, Mapes DL, Coons SJ, Carter WB.

Nephrol News Issues. 1995 Sep;9(9):29, 36. No abstract available.

PMID:
7501032
47.

Barriers to screening: the theory of reasoned action applied to mammography use in a military beneficiary population.

Michels TC, Taplin SM, Carter WB, Kugler JP.

Mil Med. 1995 Sep;160(9):431-7.

PMID:
7478025
48.

Development of the kidney disease quality of life (KDQOL) instrument.

Hays RD, Kallich JD, Mapes DL, Coons SJ, Carter WB.

Qual Life Res. 1994 Oct;3(5):329-38.

PMID:
7841967
49.

Role of selective arteriography in the diagnosis of a ruptured middle colic artery aneurysm.

Dravid VS, Sullivan KL, Carter WB, Carabasi RA, Needleman L.

Cardiovasc Intervent Radiol. 1994 May-Jun;17(3):167-9.

PMID:
8087836
50.

Supplemental Content

Loading ...
Support Center